Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics on the deal. Janux Therapeutics, a developer of safe, effective novel immunotherapies using its proprietary Tumor Activated T...
Janux Therapeutics’ $56 Million Series A Financing
Cullgen Inc.’s $50 Million Series B Financing
Wilson Sonsini Goodrich & Rosati advised Cullgen Inc. on the deal. Cullgen Inc., a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE™...
Vividion Therapeutics’ $135 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics, Inc. and the lead investors on the deal. Vividion Therapeutics, Inc., a biotechnology company utilizing novel discovery technologies...
Excision BioTherapeutics’ $60 Million Financing
Wilson Sonsini Goodrich & Rosati advised Excision BioTherapeutics on the deal. Excision BioTherapeutics, a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives,...